• 1
    Arroliga AC, Podell DN, Matthay RA. Pulmonary manifestations of scleroderma. J Thorac Imaging 1992; 7: 3045.
  • 2
    Black CM, du Bois RM. Organ involvement: pulmonary. In: ClementsPJ, FurstDE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996. p. 299331.
  • 3
    D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 42840.
  • 4
    Marie I, Lévesque H, Dominique S, Hatron PY, Michon-Pasturel U, Remy-Jardin M, et al. Atteinte pulmonaire au cours de la sclérodermie systémique. I. Pneumopathie interstitielle chronique fibrosante. Rev Med Interne 1999; 20: 100416.
  • 5
    Marie I, Lévesque H, Hatron PY, Dominique S, Courtois H. Atteinte pulmonaire au cours de la sclérodermie systémique. II. Hypertension artérielle pulmonaire isolée, cancer bronchopulmonaire, hémorragie alvéolaire. Rev Med Interne 1999; 20: 101727.
  • 6
    McCarthy DS, Baragar FD, Dhingra S, Sigurdson M, Sutherland JB, Rigby M, et al. The lungs in systemic sclerosis (scleroderma): a review and new information. Semin Arthritis Rheum 1988; 17: 27183.
  • 7
    Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 75967.
  • 8
    Silver RM. Scleroderma: clinical problems. The lungs. Rheum Dis Clin North Am 1996; 22: 82540.
  • 9
    Silver RM. Interstitial lung disease of systemic sclerosis. Int Rev Immunol 1995; 12: 28191.
  • 10
    Vallance DK, Lynch JP III, McCune WJ. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis. Curr Opin Rheumatol 1995; 7: 17482.
  • 11
    Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 40313.
  • 12
    Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 26605.
  • 13
    De Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma: a long-term followup study. Arthritis Rheum 1987; 30: 64350.
  • 14
    Greenwald GI, Tashkin DP, Gong H, Simmons M, Duanns S, Furst DE, et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Am J Med 1987; 83: 8392.
  • 15
    Lally EV, Jimenez SA, Kaplan SR. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 1988; 18: 113.
  • 16
    Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 13948.
  • 17
    Peters-Golden M, Wise RA, Schneider P, Hochberg MC, Stevens MB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984; 63: 22131.
  • 18
    Sfikakis PP, Kyriakidis M, Vergos C, Papazoglou S, Georgiakodis F, Toutouzas P, et al. Diffusing capacity of the lung and nifedipine in systemic sclerosis. Arthritis Rheum 1990; 33: 16349.
  • 19
    Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 4706.
  • 20
    Simeon CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 7238.
  • 21
    Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 76570.
  • 22
    Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 12839.
  • 23
    Medsger TA Jr, Masi AT, Rodnan GP, Benedek TJ, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 36976.
  • 24
    Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42: 116878.
  • 25
    Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 74351.
  • 26
    Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, et al. Elevated levels of platelet derived growth factor and transforming growth factor-β1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995; 22: 187683.
  • 27
    Majumdar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999; 14: 2517.
  • 28
    Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 63540.
  • 29
    Avila JJ, Lympany A, Pantelidis P, Welsh KI, Black CM, du Bois RM. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999; 20: 10612.
  • 30
    Briggs DC, Vaughan RW, Welsh KI, Myers A, du Bois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 6612.
  • 31
    Haustein UF, Anderegg U. Silica induced scleroderma—clinical and experimental aspects. J Rheumatol 1998; 25: 191726.
  • 32
    Lynch CJ, Singh G, Whiteside TL, Rodnan GP, Medsger TA Jr, Rabin BS. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). J Clin Immunol 1982; 2: 3148.
  • 33
    Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000; 43: 163340.
  • 34
    Silman AJ. Epidemiology of scleroderma. Curr Opin Rheumatol 1991; 3: 967-72.
  • 35
    Silman AJ, Jones S. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis 1992; 51: 13224.
  • 36
    Denis P, Ducrotté P, Pasquis P, Lefrançois R. Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 1981; 42: 214.
  • 37
    Jiranek GC, Bredfelt JE. Organ involvement: gut and hepatic manifestations. In: ClementsPJ, FurstDE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996. p. 45382.
  • 38
    Johnson DA, Drane WE, Curran J, Cattau EL, Ciarleglio C, Khan A, et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989; 149: 58993.
  • 39
    Lock G, Holstege A, Lang B, Schölmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997; 92: 76371.
  • 40
    Sjogren RW. Gastrointestinal motility disorders in scleroderma [review]. Arthritis Rheum 1994; 37: 1265-82.
  • 41
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 42
    Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 43
    Marie I, Levesque H, Ducrotté P, Denis P, Benichou J, Hellot M-F, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 1998; 41: 187483.
  • 44
    Ollyo JB, Lang F, Fontolliet C, Monnier P. Savary-Miller's new endoscopic grading of reflux-oesophagitis: a simple, reproducible, logical, complete and useful classification [abstract]. Gastroenterology 1990; 98 Suppl: A100.
  • 45
    Patti MG, Debas HT, Pellegrini CA. Esophageal manometry and 24-hour pH monitoring in the diagnosis of pulmonary aspiration secondary to gastroesophageal reflux. Am J Surg 1992; 163: 4016.
  • 46
    Quanjer PH. Clinical respiratory physiology: standardized lung function testing. Working party report: standardization of lung function tests. Bull Eur Physiopathol Respir 1983; 19 Suppl 5: 195.
  • 47
    Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994; 24: 2939.
  • 48
    Cohen S, Laufer I, Snape WJ, Shiau YF, Levine GM, Jimenez S. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology 1980; 79: 15566.
  • 49
    Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJC. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987; 93: 3115.
  • 50
    Maddern GJ, Horowitz M, Jamieson GG, Chatterton BE, Collins PJ, Roberts-Thomson P. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology 1984; 87: 9226.
  • 51
    Marie I, Levesque H, Ducrotté P, Denis P, Hellot MF, Benichou J, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001; 96: 7783.
    Direct Link:
  • 52
    Murphy JR, McNally P, Peller P, Shay SS. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. Dig Dis Sci 1992; 37: 83341.
  • 53
    Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol 1972; 58: 3044.
  • 54
    Chernow B, Johnson LF, Janowitz WR, Castell DO. Pulmonary aspiration as a consequence of gastroesophageal reflux: a diagnostic approach. Dig Dis Sci 1979; 24: 83944.
  • 55
    Donnelly RJ, Berrisford RG, Jack CIA, Tran JA, Evans CC. Simultaneous tracheal and esophageal pH monitoring: investigating reflux-associated asthma. Ann Thorac Surg 1993; 56: 102934.
  • 56
    Ducoloné A, Vandevenne A, Jouin H, Grob JC, Coumaros D, Meyer C, et al. Gastroesophageal reflux in patients with asthma and chronic bronchitis. Am Rev Respir Dis 1987; 135: 32732.
  • 57
    Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100: 395405.
  • 58
    Larrain A, Carrasco E, Galleguillos F, Sepulveda R, Pope CE. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99: 13305.
  • 59
    Mansfield LE, Stein MR. Gastroesophageal reflux and asthma: a possible reflex mechanism. Ann Allergy 1978; 41: 2246.
  • 60
    Mansfield LE. Gastroesophageal reflux and diseases of the respiratory tract: a review. J Asthma 1989; 26: 2718.
  • 61
    Mays EE, Dubois JJ, Hamilton GB. Pulmonary fibrosis associated with tracheobronchial aspiration: a study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976; 69: 5125.
  • 62
    Meier-Sydow J, Weiss SM, Buhl R, Rust M, Raghu G. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15: 7796.
  • 63
    Pearson JEG, Wilson RSE. Diffuse pulmonary fibrosis and hiatus hernia. Thorax 1971; 26: 3005.
  • 64
    Perrin-Fayolle M. Gastroesophageal reflux and chronic respiratory disease in adults. Clin Rev Allergy 1990; 8: 45769.
  • 65
    Richter JE. Typical and atypical presentations of gastroesophageal reflux disease: the role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am 1996; 25: 75102.
  • 66
    Schnatz PF, Castell JA, Castell DO. Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy. Am J Gastroenterol 1996; 91: 17158.
  • 67
    Simpson WG. Gastroesophageal reflux disease and asthma: diagnosis and management. Arch Intern Med 1995; 155: 798803.
  • 68
    Sontag SJ, O'Connel S, Khandelwal S, Miller T, Nemchausky B, Schnell TG, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99: 61320.
  • 69
    Tobin RW, Pope CE II, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 18048.
  • 70
    Tuchman DN, Boyle JT, Pack AI, Schwartz J, Kokonos M, Spitzer AR, et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology 1984; 87: 87281.
  • 71
    Troshinsky MB, Kane GC, Varga J, Cater JR, Fish JE, Jimenez SA, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121: 610.